Unger T, Azizi M, Belz G G
Institute of Pharmacology, Christian Albrechts University, Kiel, Germany.
J Hum Hypertens. 2000 Oct;14 Suppl 2:S23-31. doi: 10.1038/sj.jhh.1001070.
The development of angiotensin-converting enzyme inhibitors and selective angiotensin type 1 (AT1)-receptor antagonists has provided new insights into understanding the mechanism of the renin-angiotensin system (RAS) in the pathophysiology of cardiovascular disease. There is good evidence from meta-analyses that shows that inhibition of the RAS achieves organ protection features that go beyond blood pressure control. Candesartan cilexetil, a new angiotensin II receptor antagonist, is characterised by its tight binding to and slow dissociation from the AT1 receptor, and high antagonistic potency, resulting in long-lasting antagonistic effects. It is anticipated that these pharmacological characteristics may bring additional benefits to patients, not only for the management of essential hypertension but also for the management of end-organ damage.
血管紧张素转换酶抑制剂和选择性血管紧张素1型（AT1）受体拮抗剂的研发，为理解肾素-血管紧张素系统（RAS）在心血管疾病病理生理学中的机制提供了新的见解。荟萃分析有充分证据表明，抑制RAS可实现超出血压控制的器官保护作用。新型血管紧张素II受体拮抗剂坎地沙坦酯，其特点是与AT1受体紧密结合且解离缓慢，拮抗效力高，从而产生持久的拮抗作用。预计这些药理学特性可能给患者带来更多益处，不仅用于原发性高血压的治疗，还可用于终末器官损伤的治疗。
